Understanding diagnostic tests. P.J. Devereaux, MD, PhD McMaster University

Similar documents
Hayden Smith, PhD, MPH /\ v._

THERAPEUTIC REASONING

Probability Revision. MED INF 406 Assignment 5. Golkonda, Jyothi 11/4/2012

Biochemical investigations in clinical medicine

Evidence-Based Medicine: Diagnostic study

Chapter 10. Screening for Disease

Diagnostic Reasoning: Approach to Clinical Diagnosis Based on Bayes Theorem

Health Studies 315: Handouts. Health Studies 315: Handouts

Evidence Based Medicine: Articles of Diagnosis

Providing High Value Cost-Conscious Care:

The cross sectional study design. Population and pre-test. Probability (participants). Index test. Target condition. Reference Standard

Introductions. Rational Use of Diagnostic Tests: From the Old Standards to the Latest in Genetic Testing. Goals of this Workshop 8/12/2010

A qualitative approach to Bayes theorem

Sensitivity, Specificity, and Relatives

Bioengineering and World Health. Lecture Twelve

Evidence Based Medicine Prof P Rheeder Clinical Epidemiology. Module 2: Applying EBM to Diagnosis

Sensitivity, Specificity and Predictive Value [adapted from Altman and Bland BMJ.com]

Evidence-based Cancer Screening & Surveillance

Clinical Guide - Suspected PE (Reviewed 2006)

Rapid Disposition of Chest Pain Patients February 2019

Introduction to Epidemiology Screening for diseases

For more information about how to cite these materials visit

Choosing the Appropriate Stress Test: Brett C. Stoll, MD, FACC February 24, 2018

The NICE chest pain guideline 1 year on. Jane S Skinner Consultant Community Cardiologist The Newcastle upon Tyne Hospitals NHS Foundation Trust

Data that can be classified as belonging to a distinct number of categories >>result in categorical responses. And this includes:

Heart disease remains the leading cause of morbidity and mortality in industrialized nations. It accounts for nearly 40% of all deaths in the United

OCW Epidemiology and Biostatistics, 2010 Michael D. Kneeland, MD November 18, 2010 SCREENING. Learning Objectives for this session:

Biosta's'cs Board Review. Parul Chaudhri, DO Family Medicine Faculty Development Fellow, UPMC St Margaret March 5, 2016

HEART CONDITIONS IN SPORT

7/17/2013. Evaluation of Diagnostic Tests July 22, 2013 Introduction to Clinical Research: A Two week Intensive Course

SYSTEMATIC REVIEWS OF TEST ACCURACY STUDIES

Statistics, Probability and Diagnostic Medicine

Lecture 14 Screening tests and result interpretation

What Every Chief Resident Should Know About Clinical Reasoning

Questionnaire design. Questionnaire Design: Content. Questionnaire Design. Questionnaire Design: Wording. Questionnaire Design: Wording OUTLINE

RANDOLPH E. PATTERSON, MD, FACC, STEVEN F. HOROWITZ, MD, FACC*

Diagnostic tests, Laboratory tests

Critical reading of diagnostic imaging studies. Lecture Goals. Constantine Gatsonis, PhD. Brown University

MAESTRO TRIAL FINAL RESULTS. Gisela L.G. Menezes, MD, PhD

Critical Appraisal of a Diagnostic Paper (Diagnosis of Lumbar Spinal Stenosis)

Biomedical Engineering for Global Health

Worksheet for Structured Review of Physical Exam or Diagnostic Test Study

Simple Probabilistic Reasoning

Diagnosis of Venous Thromboembolism

Diagnostic Algorithms

1 Economic Models for Stable Chest Pain

sickness, disease, [toxicity] Hard to quantify

Bayes Theorem and diagnostic tests with application to patients with suspected angina

BIOE 301. Lecture Eleven

BIOE 301. The Burden of Cancer: U.S. Four Questions. Lecture Eleven. Three Case Studies. Outline. U.S. Cancer Incidence & Mortality 2009

Preclinical Detection of CAD: Is it worth the effort? Michael H. Crawford, MD

The recommended method for diagnosing sleep

EBM Diagnosis. Denise Campbell-Scherer Stefanie R. Brown. Departments of Medicine and Pediatrics University of Miami Miller School of Medicine

Chest Pain in Women ;What is Your Diagnostic Plan? No Need for Noninvasive Test

MEDICAL SCORING FOR BREAST CANCER RECURRENCE. Nurul Husna bt Jamian UiTM (Perak), Tapah Campus

THE USE OF PLEURAL FLUID CHOLESTEROL IN IDENTIFYING THE TYPE OF PLEURAL EFFUSION

Pulmonary Embolism. Thoracic radiologist Helena Lauri

Submitted: February 15, 2013 Posted: March 16, 2013

Screening (Diagnostic Tests) Shaker Salarilak

Should We Screen for Bladder Cancer in a High Risk Population: A Cost per Life-Year Saved Analysis?

How to investigate (Cardiac) Chest Pain

Cardiac evaluation for the noncardiac. Nathaen Weitzel MD University of Colorado Denver Dept of Anesthesiology

The 2016 NASCI Keynote: Trends in Utilization of Cardiac Imaging: The Coronary CTA Conundrum. David C. Levin, M.D.

INTRODUCTION TO MACHINE LEARNING. Decision tree learning

Cardiac Pathology & Rehabilitation

Contra-indications, Risks, and Safety Precautions for Stress Testing. ACSM guidelines, pg 20 7 ACSM RISK FACTORS. Risk Classifications pg 27

Diagnostic Algorithms in VTE

Critical Review Form Meta-analysis

Mariska Leeflang Birmingham, 19 July 2016

Prevention Live sensibly, among a thousand people only one dies a natural death, the rest succumb to irrational modes of living. Maimonides,

Diagnostic and Prognostic Value of Coronary Ca Score

Nuclear Perfusion Imaging of Angina

Coronary Plaque Sealing: The DEFER Study and more...

Chronic Mesenteric Ischemia

Provider Led Entity. CDI Quality Institute PLE Chest / Pulmonary Embolus AUC 07/31/2018

Stress ECG is still Viable in Suleiman M Kharabsheh, MD, FACC Consultant Invasive Cardiologist KFHI KFSHRC-Riyadh

Transurethral resection of a bladder tumour (TURBT)

Troponin = 35. Objectives. Low Risk Chest Pain. Does this patient have ACS? Does this patient have ACS? Objectives

Clinical Decision Analysis

When Should I Order a Stress Test or an Echocardiogram

Clinical Utility of Likelihood Ratios

Assessment of diabetic retinopathy risk with random forests

PRECISION IMAGING: QUANTITATIVE, MOLECULAR AND IMAGE-GUIDED TECHNOLOGIES

Non ST Elevation-ACS. Michael W. Cammarata, MD

Proposed Expansion of the Patient Safety Indicator Set Patrick S. Romano, MD MPH UC Davis/USA

Deppen S, et al. Annals of Thoracic Surgery 2011;92:

Christina Martin Kazi Russell MED INF 406 INFERENCING Session 8 Group Project November 15, 2014

12 th Annual West Virginia ACC Meeting April 8, 2017

DATE: 25 March, Healthcare Hamilton, Ontario, Canada. University, Hamilton, Ontario, Canada

An Approach to Chest Pain

Diagnostic Test. H. Risanto Siswosudarmo Department of Obstetrics and Gynecology Faculty of Medicine, UGM Jogjakarta. RS Sardjito

Live or Die by the Guidelines: ICD-9-CM

FFR-CT Not Ready for Primetime

Physiologic Assessment by Cardiac CT

Use of Nuclear Cardiology in Myocardial Viability Assessment and Introduction to PET and PET/CT for Advanced Users

Patient-centered Imaging in Coronary Artery Disease. Jason H Cole, MD, MS, FACC January 10, 2015

Patient referral for elective coronary angiography: challenging the current strategy

Chest Pain. Dr Robert Huggett Consultant Cardiologist

Prostate Cancer. Biomedical Engineering for Global Health. Lecture Fourteen. Early Detection. Prostate Cancer: Statistics

EVIDENCE-BASED GUIDELINE DEVELOPMENT FOR DIAGNOSTIC QUESTIONS

Transcription:

Understanding diagnostic tests P.J. Devereaux, MD, PhD McMaster University

Goals Understand sensitivity and specificity inform why they are in general problematic Discuss likelihood ratios Inform pretest and posttest probabilities of disease Understand testing and treatment thresholds Go through case examples convince you that understanding diagnostic properties is essential to good clinical practice

Diagnostic Tests: Definitions Gold Standard Disease present Disease absent Test positive (+ve) Test negative (-ve)( (a) True positive (TP) (c) False negative (FN) (b) False positive (FP) (d) True Negative (TN) Sensitivity: proportion of people with disease who have +ve test Sensitivity= TP = a. TP+FN a+c SNOUT-Sensitive test, Negative result rule OUT disease Specificity: proportion of people free of disease who have -ve test Specificity= TN = d. TN+FP d+b SPIN-Specific test, Positive result rules IN disease

Disease present Disease absent Test positive (+ve) Test negative (-ve)( (a) True positive (TP) (c) False negative (FN) (b) False positive (FP) (d) True Negative (TN) Post-test probability = of disease given a positive result Post-test probability = of disease given a negative result TP = a. TP+FP a+b FN = c. FN+TN c+d

Likelihood ratios Positive likelihood ratio (+ve LR) = LR for +ve test - defined as likelihood of +ve test among individuals with disease, relative to likelihood of +ve test among those without disease Negative likelihood ratio (-ve LR) = LR for ve test - defined as likelihood of -ve test among individuals with disease, compared to probability of -ve test among those without disease Cystoscopy (Reference Test) NMP 22 Result Bladder Cancer No Bladder Cancer Positive 44 179 Negative 35 1073 Total 79 1252 Likelihood ratio for positive test result = (44/79)/(179/1252) = 3.90 Likelihood ratio for negative test result = (35/79)/(1073/1252)] = 0.52

Coronary Artery Disease (CAD) This example will deal with exercise stress testing (EST) in diagnosis of CAD Before testing we need to make some cut off points for post-test probability of disease given a +ve or ve test o such that we will except as being truly positive, negative, or still indeterminate What we are talking about is referred to as testing and treatment thresholds

Testing and treatment thresholds Reason for this decision is that we are not using gold standard test which tell us disease present or absent with certainty We are using another test which is not 100% accurate therefore you will never be 100% confident that disease is present or absent after test However, accurate tests can sometimes get you very close to 100% confident of your diagnosis With this in mind lets set some cut off points so that after the test we can tell patient a. They have CAD and need treatment with drug X b. They do not have CAD and can rest assured c. They still remain in an uncertain category, where more testing is needed

Case 35y/o male presents to your office with 3 month hx of substernal chest pain, predictably brought on with exertion lasts 45 minutes before resolving with rest What is his pretest probability of CAD?

CAD % probability of > 75% coronary stenosis Symptoms: 1. Substernal location 2. Brought on by exertion 3. Relieved in <ten minutes by rest or nitroglycerin Asymptomatic MEN (0 symptoms) WOMEN (1 symptom) MEN WOMEN (2 symptoms) MEN WOMEN Typical angina MEN (all 3 Sx) WOMEN Ages: 30-39 40-49 50-59 60-69 2%.3% 5% 1% 22% 4% 70% 26% 6% 1% 14% 3% 46% 13% 87% 55% 10% 3% 22% 8% 59% 32% 92% 79% 12% 8% 28% 19% 67% 54% 94% 91%

EST Next, you decide to do an EST and he gets 1.7 mm of ST depression What is the specificity? 98% What is the sensitivity? 9%

What do you tell him? 1. He has CAD and needs drug X 2. He does not have CAD and can rest assured 3. He is in an uncertain category and needs further testing

Post-test probability of CAD To determine his post-test probability of disease start by setting up 2X2 table with knowledge that his pretest likelihood of disease was 21.8% this value corresponds to # of people with disease

CAD Present 218 Absent 782 EST + ve TP FP EST ve FN TN Sensitivity (9%) = TP TP+FN (218) Therefore, TP=19 and FN=218-19=199 Specificity (98%) = TN Therefore, TN=766 and FP=782-766=16 TN+FP (782)

Now table looks like EST+ve EST-ve Present 218 TP (19) FN (199) Absent 782 FP (16) TN (766) Post-test probability = TP = 19 = 54% of disease given this TP+FP 19+16 positive results

Case 45 y/o female with history of epigastric pain undergoes endoscopy and this reveals 2 cm duodenal ulcer biopsy taken for clo test, comes back -ve What is her pretest probability of H. pylori? What is the sensitivity of clo test? What is the specificity of clo test?

What would you tell her? 1. She needs Tx for H. pylori 2. She does not need Tx for H. pylori 3. She needs further investigations

Post-test probability of H.pylori To determine her post-test probability of H. pylori start by setting up a 2X2 table with knowledge that her pretest likelihood was 95% this value would therefore correspond to the # of people with disease

H. PYLORI Present 950 Absent 50 Clo test +ve TP FP Clo test ve FN TN Sensitivity (95%) = TP Therefore, TP = 902 and FN = 950-902=48 TP+FN (950) Specificity (98%) = TN Therefore, TN = 49 and FP = 50-49=1 TN+FP (50)

Now table looks like Clo test +ve Clo test ve Present 950 TP (902) FN (48) Absent 50 FP (1) TN (49) Post-test probability = FN = 48 = 49% of disease given this FN+TN 48+49 positive results

Now use likelihood ratios For question 1 the finding of 1.7 mm of ST Depression has LR=4.2 Start off by finding pretest probability of disease on left-hand column Then place a ruler through LR in center column and read off post-test likelihood in right hand column

Summary In clinical decision making sensitivity and specificity have substantial limitations likelihood ratios are practical Pretest probability is important to inform post- test probability Understand testing and treatment thresholds can facilitate consistency in clinical care Understanding diagnostic properties is essential to good clinical practice

Searching for studies evaluating diagnostic tests OVID click on limits and find clinical queries then click on diagnosis (sensitivity) or diagnosis (specificity) depending on your goal PubMed on left hand side of page find PubMed Services click on clinical queries and then click on search by clinical study category next under category click on diagnosis and then under scope click specific search or sensitive search depending on your goal

Resources for evaluating diagnostic tests Empirical evidence of design-related bias in studies of diagnostic tests JAMA September 1999;282:1061-1066 MOST IMPORTANT RESOURCE FOR YOU TO BUY Diagnostic Strategies for Common Medical Problems. Editor: Robert J. Panzer

Likelihood ratios 1. Pulmonary embolism: V/Q scanning High probability: 18.3 Intermediate probability: 1.2 Low probability: 0.36 Normal/near normal 0.10 2. DVT: IPG Duplex U/S -L.R. = 0.05 -L.R. = 0.07 +L.R. = 19 +L.R. = 47 3. Exudative pleural effusion: LDH ratio > 0.6 Protein ratio > 0.5 -L.R. = 0.14 -L.R. = 0.10 +L.R. = 43 +L.R. = 45

Disease present Disease absent Test positive (+ve) Test negative (-ve)( (a) True positive (TP) (c) False negative (FN) (b) False positive (FP) (d) True Negative (TN) Positive predictive (+PV) value: proportion of people with +ve tests who have disease +PV= TP = a. TP+FP a+b +PV = post-test probability of disease given +ve result Negative predictive (-PV) value: proportion of people with -ve test who are free of disease. -PV= TN = d. FN+TN c+d 100-(-PV)= post-test probability of disease given -ve test